A fermented product and its application in weight loss and immunity enhancement

By screening and fermenting Bacillus subtilis-1, freeze-dried products containing extracellular vesicles were prepared, which solved the problem of the limited application fields of existing Bacillus subtilis and achieved significant weight loss and immunity enhancement effects, which are suitable for animal feed, health products and pharmaceuticals.

CN118356445BActive Publication Date: 2024-11-26ZHONGKE REBIRTH (XIONGAN) BIOTECHNOLOGY CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202311754525.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-05-18
Publication Date
2024-11-26
Estimated Expiration
2042-05-18

AI Technical Summary

Technical Problem

The existing applications of Bacillus subtilis are limited, making it difficult to effectively promote macrophage proliferation and inflammatory factor expression, and its fermentation products have no significant effects on weight loss and boosting immunity.

Method used

A strain of Bacillus subtilis-1 (CGMCC No. 20831) was screened and identified. A freeze-dried product containing extracellular vesicles was prepared by a specific fermentation method. The product contains high levels of fibrinolytic enzyme, oryzanol, polysaccharides, water-soluble cellulose, and niacin, and can be used to prepare weight loss and immunity-boosting products.

Benefits of technology

The fermentation products of this strain significantly promote macrophage proliferation and inflammatory factor expression, and have significant effects on weight loss and immunity enhancement. They can alleviate the problems of abnormal blood sugar and blood lipids and decreased immunity in obese rats.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118356445B_ABST
    Figure CN118356445B_ABST
Patent Text Reader

Abstract

The present application discloses a strain of Bacillus subtilis, a fermented product and its application in weight loss and immunity enhancement. The strain is deposited in the General Microbiological Center of China Microbiological Culture Collection Administration, with the deposit number CGMCC No.20831 and the classification name Bacillus subtilis Bacillus subtilis ‑1, the deposit date is September 25, 2020, and the deposit address is No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing. In vivo and in vitro experiments have confirmed that the fermentation product of this strain has application value in weight loss and immunity enhancement.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This application is a divisional application of "A strain of Bacillus subtilis and its application in weight loss and immunity enhancement" (application number: CN202210538106.1, application date: May 18, 2022). This application relates to the technical field of Bacillus subtilis, and in particular to a fermentation product and its application in weight loss and immunity enhancement. Background Art

[0002] Among the numerous microecological preparations, Bacillus subtilis ( B. subtilis ) is a commonly used water quality regulator and feed additive. Bacillus subtilis often exists in the form of spores. It can quickly and effectively decompose organic matter in the water by secreting a variety of extracellular enzymes such as protease, amylase, lipase, etc. Aquatic products are used as nutrients for algae growth and reproduction. Algae also produce dissolved oxygen through photosynthesis, which is used for the decomposition of organic matter and the respiratory consumption of microorganisms in the water and farmed animals, forming a good microecological environment balance. In addition, Bacillus subtilis also directly secretes a variety of antibacterial active substances such as bacteriocins, iturin, and fengycin to inhibit the growth of pathogens and achieve the purpose of purifying water quality. At the same time, Bacillus subtilis can also change the intestinal flora structure of farmed animals, improve the digestion and absorption of nutrients, and strengthen the immunity of animals.

[0003] However, exploring the resources of Bacillus subtilis strains to expand their application areas remains a research need. Summary of the invention

[0004] In view of this, the present application screened a strain of Bacillus subtilis by a special method, which can promote macrophage proliferation and cytokine expression, and its fermentation product has a weight loss effect. As a new strain resource, the Bacillus subtilis has broadened the application scope of Bacillus subtilis as a microecological preparation and has very practical application value.

[0005] In the first aspect, the present application discloses a strain of Bacillus subtilis, which is deposited in the General Microbiological Center of China Microorganism Culture Collection Administration Committee, with a deposit number of CGMCC No.20831 and is classified as Bacillus subtilis. Bacillus subtilis -1, the storage date is September 25, 2020, and the storage address is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0006] In a second aspect, the present application discloses a fermentation method using the Bacillus subtilis according to claim 1, comprising the following steps:

[0007] preparing a seed culture solution and a fermentation culture solution, wherein the seed culture solution contains wheat germ oil, and the fermentation culture solution contains wheat bran powder and wheat germ oil;

[0008] Prepare a seed suspension, the seed suspension is made from the deposited Bacillus subtilis -1 after activating the strain, inoculating it into the seed culture solution for culturing;

[0009] Obtaining a fermentation broth, wherein the fermentation broth is obtained by transferring the seed suspension to the fermentation broth for fermentation;

[0010] A dry product and vesicles are obtained, and the dry product and vesicles are both obtained by purifying the fermentation broth.

[0011] In an embodiment of the present application, the seed culture medium comprises 1.5wt% glucose, 1.0wt% peptone, 0.1wt% KH2PO4, 0.1wt% K2HPO4, 0.05wt% MgSO4, 0.02wt% CaC12 and 0.01v / v% wheat germ oil.

[0012] In an embodiment of the present application, the fermentation culture contains 1.5wt% starch, 1.5wt% wheat bran powder, 1.0wt% peptone, 0.1wt% KH2PO4, 0.1wt% K2HPO4, 0.05wt% MgSO4, 0.02wt% CaC12 and 0.01v / v% wheat germ oil.

[0013] In the embodiment of the present application, the steps of obtaining the dried product and the vesicles specifically include:

[0014] The fermentation broth was centrifuged at 4°C and 15,000×g for 20 min, and the supernatant was collected. The supernatant was ultrafiltered using a 100 KD filter membrane to obtain a filtrate and a concentrate containing extracellular vesicles;

[0015] The concentrated solution is purified to obtain extracellular vesicles;

[0016] The filtrate is subjected to suspended evaporation under reduced pressure and freeze-dried to obtain a freeze-dried product.

[0017] In the embodiment of the present application, the step of purifying the concentrated solution to obtain extracellular vesicles includes: centrifuging the concentrated solution at 4°C and 100,000×g for 10 min, and taking the supernatant;

[0018] The supernatant was placed in a density gradient centrifugation medium with a concentration gradient of 10% to 55% for density gradient ultracentrifugation at 4°C and 200,000 × g for 12 h;

[0019] By measuring the nanoparticles in each layer of the layered material obtained by centrifugation and collecting the gradient interval with more nanoparticles, the enriched vesicle particles can be obtained;

[0020] The solution in the vesicle aggregation zone is centrifuged at 4°C and 180,000×g for 2 h to enrich the precipitate to obtain the extracellular vesicles.

[0021] In a third aspect, the embodiments of the present application disclose the Bacillus subtilis -1 in the preparation of weight loss products.

[0022] In a fourth aspect, the embodiments of the present application disclose the Bacillus subtilis -1 is used in the preparation of products to enhance immunity.

[0023] In a fifth aspect, the embodiments of the present application disclose the Bacillus subtilis -1 Application in the preparation of animal feed.

[0024] Compared with the prior art, this application has at least the following beneficial effects:

[0025] The present invention obtains a strain of Bacillus subtilis from the sludge of shrimp breeding ponds. Bacillus subtilis -1CGMCC No.20831, not only has the physiological and biochemical activities of conventional Bacillus subtilis, but also can produce extracellular vesicles that promote macrophage proliferation and the expression of inflammatory factors, and ferments wheat bran powder and wheat germ oil to obtain freeze-dried products with high content of fibrinolytic enzyme activity, oryzanol, polysaccharides, water-soluble cellulose and niacin.

[0026] In addition, the present invention also confirms the Bacillus subtilis obtained by screening in the present invention through animal experiments. Bacillus subtilis -1CGMCC No.20831 can alleviate the abnormal blood sugar, blood lipid content, and liver function of obese rats, and improve the physiological activity of decreased immunity in obese rats, and has the application prospect of being used in animal feed, health products and medicines. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 Provided in the embodiments of this application Bacillus subtilis-1 The antibacterial effect of CGMCC No.20831 on Staphylococcus aureus, M represents the conventional indicator bacteria Bacillus subtilis.

[0028] Figure 2 Provided in the embodiments of this application Bacillus subtilis-1 The antibacterial effect of CGMCC No.20831 on Vibrio parahaemolyticus, M represents the conventional indicator bacteria of Bacillus subtilis.

[0029] Figure 3 Provided in the embodiments of this application Bacillus subtilis-1 CGMCC No.20831 extracellular vesicle scanning electron microscopy extracellular vesicle morphology.

[0030] Figure 4 Provided in the embodiments of this application Bacillus subtilis-1 Negatively stained electron microscopic image of extracellular vesicles of CGMCC No.20831. DETAILED DESCRIPTION

[0031] In order to make the purpose, technical scheme and advantages of the present application clearer, the present application is further described in detail below in conjunction with the examples. It should be understood that the specific embodiments described herein are only used to explain the present application and are not intended to limit the present application. The instruments or reagents not particularly described in the examples of the present application can be obtained from commercial sources.

[0032] Screening and identification of Bacillus subtilis-1

[0033] 1. Sampling and strain isolation and culture

[0034] Strain samples: collected from a shrimp breeding pond, about 1g of the bottom mud in the pond was placed in a reagent bottle containing 99mL of sterile water, shaken for 5 minutes, and sent to the laboratory in an ice bath.

[0035] Strain isolation and culture:

[0036] 1) Under sterile conditions, take 10 mL of the supernatant of the above strain sample and mix it in 100 mL of LB liquid culture medium. Culture it at 30℃ and 180r / min overnight to obtain enriched bacterial solution.

[0037] 2) Place the enriched bacterial liquid in an 80℃ water bath for 20 min. After cooling, take 1 mL and mix it with 9 mL LB liquid culture medium. Dilute it 10-fold in sequence to obtain a series of gradient suspensions.

[0038] 3) Take 100 μL of the above gradient dilution suspension and spread it on LB solid culture medium, and place it in a 30℃ constant temperature incubator for 48 hours. 4) Pick out milky white, filmy and wrinkled suspected colonies, streak them on the plate, and culture them at 30℃ for 48 hours. Repeat this operation 3 times to obtain 50 isolated strains; mix the LB bacterial solution of the 50 isolated pure strains with sterile 50% glycerol in a ratio of 4:1 to make a bacterial suspension, and freeze it at −80℃ for later use.

[0039] 2. Initial screening

[0040] The isolated strain was inoculated into LB liquid medium at an inoculum rate of 10 w / v%, and fermented at 30 °C and 180 r / min for 10 h. The fermentation broth was centrifuged at 1500 rpm for 10 min, and the bacteria were washed three times with saline. The bacterial suspension was diluted to about 10 with LB liquid medium. 8 CFU / mL.

[0041] For each isolated strain, 10 portions of this fermentation bacterial suspension were taken, poured into a flat dish, and placed in a plasma mutagen (normal pressure room temperature plasma mutagenesis breeding instrument, model ARTP-IIS, Wuxi, Jiangsu / ARTP), with the voltage set to 25 V, the current to 1.5 A, the irradiation distance to 2 mm, and the treatment time to 10 s. After the mutagenesis was completed, the bacterial solution was spread on LB medium containing 0.5% LiCL and cultured at 30°C for 12h~14h.

[0042] The lethality of the strain was calculated by the number of colonies, lethality = 1-100% × x / y, where x is the number of plate colonies after plasma and LiCL treatment, and y is the number of plate colonies without plasma and LiCL treatment. Plate colonies with a lethality of more than 90% were selected as the basis for further screening. If the lethality did not exceed 90%, the above mutagenesis step was performed again. Finally, 12 plates were screened after the above mutagenesis steps.

[0043] 3. Rescreening

[0044] The plates obtained by mutagenesis screening were inverted and cultured at 30℃ for 12-14 h. The larger colonies on the plates were picked and inoculated into the fermentation liquid medium at an inoculum of 9w / v%. The liquid medium contained 1.5wt% glucose, 1.0wt% peptone, 0.1wt% KH2PO4, 0.1wt% K2HPO4, 0.05wt% MgSO4, 0.02wt% CaC12 and 0.01v / v% wheat germ oil, pH 7.2. The culture was shaken at 37℃ for 96h. After the fermentation, the bacterial solution was centrifuged at 12000 r / min for 10 min. Staphylococcus aureus and Vibrio parahaemolyticus were used as indicator bacteria. The antibacterial diameter of the supernatant was measured by the Oxford cup method. Each group of experiments was repeated 3 times and the average value was taken.

[0045] According to the inhibition zone, 5 strains were finally screened and named 1 to 5#. The inhibition result of one strain against Staphylococcus aureus is as follows Figure 1 The results of inhibition of Vibrio parahaemolyticus are shown in Figure 2 shown. Figure 1 , 2 The Bacillus subtilis model bacteria (M) used in the experiment were purchased from China National Institute for Food and Drug Control, and the strain collection number is CMCC (B) 63501. The antibacterial results of the above five strains are shown in Table 1.

[0046] Table 1

[0047] strain Staphylococcus aureus inhibition zone / mm Vibrio parahaemolyticus inhibition zone / mm 1# 13.5±1.4 8.4±2.3 2# 14.2±0.6 12.1±1.4 3# 13.8±2.1 11.6±0.8 4# 14.5±0.2 10.5±1.6 5# 13.9±1.6 10.1±0.9

[0048] 4. Final screening

[0049] The final screening of this application is to screen the above 5 strains that can produce inhibition zones by density gradient centrifugation to screen strains that can produce extracellular vesicles. The specific steps are as follows:

[0050] (1) The five strains obtained from the above rescreening were inoculated again into the above liquid culture medium and cultured in a shaking incubator at 37°C for 96 h;

[0051] (2) The fermentation broth was centrifuged at 4°C and 15,000 × g for 20 min, the supernatant was collected, and filtered through a 0.45 μm filter membrane to collect the filtrate;

[0052] (3) The filtrate is ultrafiltered using a 100 KD filter membrane to remove macromolecular impurities such as proteins to obtain a concentrate of extracellular vesicles;

[0053] (4) Centrifuge the concentrate at 100,000 × g for 10 min at 4°C and take the supernatant.

[0054] (5) The supernatant was placed in OptiPrepTM Density Gradient Medium solution (Sigma) with a concentration gradient of 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% and 55% for density gradient ultracentrifugation at 4°C and 200,000 × g for 12 h;

[0055] (6) The particle concentration in each layer of the layered material obtained by centrifugation was measured using the Nanosight NS300 nanoparticle tracking analyzer. A certain gradient was selected as standard 1, and the relative abundance of each gradient was calculated to obtain the gradient interval with more vesicle aggregation.

[0056] (7) Take the solution from the vesicle aggregation area and centrifuge it at 4°C and 180,000 × g for 2 h to enrich the precipitate to obtain extracellular vesicles. Resuspend it in 50 mM Hepes buffer and store it at 4°C.

[0057] (8) The precipitate obtained in step (7) was dripped onto a carbon-coated copper grid, and 2% uranyl acetate was added. The mixture was dried at room temperature, and the morphology of extracellular vesicles was examined by scanning electron microscopy and negative-stain electron microscopy. The results showed that only bacteria 1 produced extracellular vesicles, such as Figure 3 , 4 shown.

[0058] 5. Identification of bacteria #1

[0059] The colony of No. 1 bacteria is milky white, nearly round, with irregular edges, rough and wrinkled. Gram staining is purple, positive, rod-shaped, blunt at both ends, with spores. Its physiological and biochemical identification results are shown in Table 1. According to the "Common Bacteria System Identification Manual", it was preliminarily identified as Bacillus subtilis.

[0060] Table 2, "+" indicates positive, "-" indicates negative

[0061] Physiological and biochemical indicators Reaction characteristics Catalase + Fermentation of arabinose to produce acid + Fermentation of glucose to produce acid + Xylose fermentation to produce acid + Fermentation of mannose to produce acid + VP determination + Indole test - Hydrolyzed Cheese + Hydrolyzed starch + Nitrate reduction + Utilize citrate + Utilizing Propionate -

[0062] The present application also uses bacterial genomic DNA as a template, and uses the universal primers 27F / 1492R of 16S rRNA gene to amplify the target band. The PCR product is detected by 1% agarose gel electrophoresis and then recovered and sent for sequencing. The 16S rRNA gene sequence is shown in SEQ ID NO.1. The sequencing sequence is compared by BLAST program. The results show that the strain is Bacillus subtilis LH36, Sequence ID: JQ917763.1, with a similarity of 99%. At the same time, combined with the morphological observation and physiological and biochemical identification results of the strain, the strain was named Bacillus subtilis Bacillus subtilis -1, deposited at the General Microbiology Center of China Microorganism Culture Collection on September 25, 2020, with the deposit number CGMCC No.20831, and the deposit address is No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing.

[0063] 16s

[0064] aggctggagaagggagcttgctccctgatgttagcggcggacgggtgagtaacacgtgg

[0065] taacctgcctgtaagactgggataactccgggaaaccggggctaataccggatggttgtt

[0066] tgaaccgcatggttcagacatattaccctggcttcggctaccacttacagatggacccgcg

[0067] gcgcatagctagttggtgaggtaacggctcaccaaggcaacgatgcgtagccgacctga

[0068] agggaatcttccgcaatggacgaaagtctgacgagcaacgccgcgtgagtgatgaaggt

[0069] cttgacggtacctaaccagaaagccacggctaactacgtgccagcagccgcggtaatacg

[0070] taggtggcaagcgttgtccggaattttgggcgtaargggctcgcaggcggtttcttaa

[0071] gtctgaagtgaaarmccaccggctcarccgggaggtcattggaaactggttaacttg

[0072] gaacaccagtggcgaagcgactctctggtctgtaactgacgctgaggagcgaagcgtg

[0073] gggaggcgtttccgccccttagtgctgcagctaacgcattwagcactcgcctggggagta

[0074] cggtcgcaagactgaaacccaaaggaattgacgggsccgcayaagcggtgtgagcatg

[0075] agagataggacgtccccttcggcccacagtgacaggtggtgcatggttgtcgtcagctc

[0076] gtcaaatcatcatgccccttatgacctgggctacacacgtgctacaatggacagaacggaa

[0077] gaatacgttcccgggccttgtacacaccgcccgtcacaccacgagagtgtaacacggg

[0078] aagtcggtgaggtaacctttagagccagccgccgaag

[0079] Bacillus subtilis -1 Fermentation characteristics

[0080] 1. Fermented seeds

[0081] The above-screened Bacillus subtilis -1 was inoculated from the preserved slant culture medium into a seed liquid culture medium and cultured at 30°C, 180 r / min for 18 h. The seed liquid culture medium contained 1.5wt% glucose, 1.0wt% peptone, 0.1wt% KH2PO4, 0.1wt% K2HPO4, 0.05wt% MgSO4, 0.02wt% CaC12 and 0.01v / v% wheat germ oil, pH 7.2-7.4.

[0082] 2. Fermentation culture

[0083] The inoculation volume was 2-8% and the inoculum was pipetted into the fermentation liquid medium with a sterilized pipette tip, the volume was 100 mL / 250 mL, and the culture was carried out at 37°C and 180 r / min for 14 hours. The fermentation liquid medium contained 1.5wt% starch, 1.5wt% wheat bran powder (purchased from Dengfeng Junao Agricultural and Sideline Products Development Co., Ltd.), 1.0wt% peptone, 0.1wt% KH2PO4, 0.1wt% K2HPO4, 0.05wt% MgSO4, 0.02wt% CaC12 and 0.01v / v% wheat germ oil, pH 7.2-7.4.

[0084] 3. Fermentation broth treatment

[0085] (1) Centrifuge the fermentation broth at 4°C and 15,000 × g for 20 min, collect the supernatant, and ultrafilter the supernatant using a 100 KD filter membrane to obtain a filtrate and a concentrate containing extracellular vesicles;

[0086] (2) Prepare a suspension of extracellular vesicles from the concentrate according to the above method;

[0087] (3) The filtrate is evaporated under reduced pressure at 50°C and freeze-dried to obtain a freeze-dried product.

[0088] This application takes the above-mentioned steps of fermentation seeds, fermentation culture and fermentation liquid treatment as Example 1.

[0089] This application also discloses Example 2, using Bacillus subtilis -1 carried out the fermentation in the same steps as Example 1, except that the fermentation liquid culture medium used was different. The fermentation liquid culture medium used in Example 2 contained 2.5wt% starch, 1.0wt% wheat bran powder, 1.0wt% peptone, 0.1wt% KH2PO4, 0.1wt% K2HPO4, 0.05wt% MgSO4, 0.02wt% CaC12 and 0.01v / v% wheat germ oil, pH 7.2~7.4.

[0090] The present application also discloses Example 3, which uses Bacillus subtilis -1 carried out the fermentation in the same steps as Example 1, except that the fermentation liquid culture medium used was different. The fermentation liquid culture medium used in Example 3 contained 1.0wt% starch, 2.2wt% wheat bran powder, 1.0wt% peptone, 0.1wt% KH2PO4, 0.1wt% K2HPO4, 0.05wt% MgSO4, 0.02wt% CaC12 and 0.01v / v% wheat germ oil, pH 7.2~7.4.

[0091] The present application also discloses Example 4, which uses Bacillus subtilis -1 carried out the fermentation in the same steps as Example 1, except that the fermentation liquid culture medium used was different. The fermentation liquid culture medium used in Example 3 contained 0.8wt% starch, 2.5wt% wheat bran powder, 1.0wt% peptone, 0.1wt% KH2PO4, 0.1wt% K2HPO4, 0.05wt% MgSO4, 0.02wt% CaC12 and 0.01v / v% wheat germ oil, pH 7.2~7.4.

[0092] This application also discloses Comparative Example 1, which uses commercial Bacillus subtilis (Deposit number CMCC(B)63501, purchased from China Inspection Institute) The same fermentation steps as in Example 1 were carried out, the seed culture medium was LB liquid culture medium, the fermentation medium contained 10 g / L glucose, 15 g / L beef extract and 5 g / L K2HPO4, pH 7.0.

[0093] This application also discloses Comparative Example 2, which uses commercial Bacillus subtilis (Deposit number CMCC(B)63501, purchased from China National Institute for Food and Drug Control) The same fermentation steps as in Example 1 were performed, and the seed culture medium and fermentation medium were the same as in Example 1.

[0094] 4. Testing of freeze-dried products

[0095] (1) Fibrinogen plate method to measure plasmin activity

[0096] For the test sample, the freeze-dried product provided in the examples or comparative examples of the present application was fully dissolved with pH 7.8 pBS, extracted at 4°C for 4 h, centrifuged at 8000 r / min for 20 min, and the supernatant was taken as the test sample.

[0097] Prepare 100 mL of 0.5wt% agarose solution (Sigma) and keep it in a 55℃ water bath for 30 min. Prepare 60 mL of 0.5mg / mL fibrinogen solution (Sigma) and keep it in a 40℃ water bath for 20 min. After quickly mixing the agarose solution and fibrinogen solution, add 5 mL of 7.5 BP / mL thrombin solution (Sigma) and pour it into a culture dish with a diameter of 1.5 mm. After sufficient coagulation, keep it in a 80℃ for 30 min to inactivate thrombin. Cool it and set it aside. Then punch holes, spot the sample, and place it in a 37℃ wet box for 18 hours. Determine the size of the lysozyme circle and calculate the area. After spotting urokinase with different activities (purchased from the China Food and Drug Administration and Biological Products), the size of the lysozyme circle is measured. The concentration and the size of the lysozyme circle are used to make a standard curve, and the standard equation is fitted. Then the sample is spotted in the same way to calculate the area of ​​the lysozyme circle of the sample, and then the fibrinolytic activity in the sample is calculated. (2) Determination of oryzanol content

[0098] Test sample: Accurately weigh 50 mg of freeze-dried sample, extract with 15 mL of methanol, and centrifuge at 4°C, 3000 rpm for 15 min. After multiple treatments, combine the supernatants, evaporate under reduced pressure to less than 3 mL, and then make up to 5 mL with methanol. Pass through a 0.22 μm filter membrane, and measure the oryzanol content in the solution by HPLC.

[0099] HPLC chromatographic conditions: Ultimate XB-NH2 (GD) column (4.6 mm × 250 mm, 5 μm), mobile phase: chromatographic grade ethanol, flow rate 0.6 mL / min, column temperature: 40 °C, detection wavelength 327 nm, injection volume 10 μL.

[0100] (3) Determination of polysaccharide content

[0101] Test sample: Take 13g of freeze-dried product, add 280mL petroleum ether, defatted twice at 85℃, 2h each time, evaporate the petroleum ether from the residue to obtain defatted product. Then add 200mL of distilled water to the defatted product, heat and reflux for 4.5h, combine the filtrate, concentrate to obtain 53mL of concentrate, add 34mg of Taka amylase (Sigma, EC:3.2.1.1 (BRENDA, IUBMB)), react in a 50℃ water bath for 90min, centrifuge at 4℃, 3000rpm for 15min, and take the clear solution. Add 3 times the volume of 95% ethanol, mix thoroughly, centrifuge at 4℃, 2000rpm for 20min, and combine the precipitates after multiple treatments; then dissolve the precipitate with a small amount of distilled water, remove impurities with Sevag reagent (chloroform / n-butanol 4 / 1), repeat the operation 3 times, and combine the supernatants. Add three times the volume of 95% ethanol for alcohol precipitation, take the precipitate and wash it repeatedly with ether. The product obtained after drying is the test sample, which is configured into a 20 mg / mL solution.

[0102] Standard solution: 20 mg / mL glucose solution. The polysaccharide content in the test sample was determined by the phenol-sulfuric acid method.

[0103] (4) Water-soluble cellulose

[0104] Test sample: Rinse the freeze-dried product with petroleum ether to remove fat, then add 10mL 85% ethanol to each gram of sample and mix well to remove sugar. This process can be repeated multiple times, and finally dried in an oven at 40°C to serve as the test sample. Test: Take the dried powder and prepare a 25mg / mL solution with MES-TRIS buffer (two parallel solutions), add 5v / v% Taka amylase, shake in a water bath at 80℃ for 30 min, cool to 60℃ and add 5v / v% protease (Sigma, EC number: 232-642-4), shake at 60℃ for 30 min, adjust pH to 4.0-4.7, then add 5v / v% amyloglucosidase (Sigma, EC number: 232-877-2), shake at 60℃ for 30mm; add 95% ethanol preheated to 60℃ to the solution after reaction at a ratio of 4:1, and precipitate at room temperature for 1h. Centrifuge at 3000rpm for 15min, dry the precipitate and weigh it, which is the residue weight (the two parallel solutions correspond to M1 and M2 respectively). Take one portion of the residue to determine the protein content (BCA method), which is M3; the other portion of the residue was burned at 525℃ for 5h, and the ash weight was measured as M4; then the formula is: dietary fiber (DF) content (g / 100g) = {[(M1+M2) / 2]-M3-M4} / [(M1+M2) / 2]×100

[0105] (5) Determination of niacin content

[0106] Preparation of the test sample: Accurately weigh 20.0 g of the freeze-dried product into a 100 mL conical flask, add 40 mL of a mixed solvent (methanol-0.01 mol / L hydrochloric acid solution with a volume ratio of 80:20), filter after ultrasonic extraction for 30 min, repeat the extraction twice under the same conditions for the residue, and combine the extracts; evaporate and concentrate on a rotary evaporator, extract the obtained concentrate twice with anhydrous ether for defatting, take the aqueous phase, filter with a 0.22 μm filter membrane, and make up to volume with a 25 mL volumetric flask to obtain the test sample solution.

[0107] Preparation of standard curve: Prepare 10 mg / mL, 20 mg / mL, 30 mg / mL, 40 mg / mL, 50 mg / mL, 60 mg / mL, 70 mg / mL and 80 mg / mL niacin (Sigma, EC number: 200-441-0) solutions as standard solutions, perform HPLC detection, and prepare a standard curve.

[0108] HPLC chromatographic conditions: The chromatographic column used was Cosmosil Waters SC18-PAQ (4.6×250 mm), the column temperature was 25°C, the mobile phase was 0.1% phosphoric acid aqueous solution-methanol system, the volume ratio was 88:12, the flow rate was 0.6 mL / min, and the analysis wavelength was 266 nm.

[0109] 5. Immunoreactivity of vesicle suspension

[0110] (1) Detection of cell proliferation by CCK-8 method DC2.4 cells (Cat. No. CL-0545, Prosai) and Raw264.7 cells (Cat. No. CL-0190, Prosai) were revived and subcultured, cell suspensions were prepared, and cell counts were performed.

[0111] The above two types of cells were seeded in 96-well plates, with 1×10 5 Cells, about 100 μL cell suspension, cultured in a 37 ° C incubator for 24 h, discarded the supernatant on the second day, washed 3 times with PBS, added medium containing 10 μg / mL vesicles and incubated for 24 h, and set up negative control (containing only cells and medium) and blank control (containing only medium). The next day, 10 μL CCK-8 was added to each well, and the absorbance at 450 nm was measured after 4 hours of culture. Cell proliferation index = (A1-A0) / (A2-A0); where A2 represents the absorbance value of the negative control group, A1 represents the absorbance value of the test group, and A0 represents the absorbance value of the blank control group.

[0112] Since no obvious vesicle production was detected in Comparative Examples 1 and 2, the commercial Bacillus subtilis CMCC(B)63501 (10 μg bacterial powder / mL) provided in Comparative Examples 1 and 2 was co-cultured with DC2.4 cells and Raw264.7 cells, respectively, to determine its effect on the proliferation of the two cells.

[0113] Real-time fluorescence quantitative PCR detection of inflammatory factor transcription levels in Raw264.7 cells

[0114] After the Raw 264.7 cells were revived and subcultured, a Raw 264.7 cell suspension was prepared and the cells were counted. Raw 264.7 cells were seeded in a 12-well plate at 1×10 5 Cells were added with 5 μg / mL vesicles and incubated for 24 h. A negative control (containing only cells and culture medium) and an empty control (containing only culture medium) were also set up.

[0115] Since no obvious vesicle production was detected in Comparative Examples 1 and 2, the commercial Bacillus subtilis CMCC(B)63501 (10 μg bacterial powder / mL) provided in Comparative Examples 1 and 2 was co-cultured with Raw264.7 cells to determine its effect on the transcription level of inflammatory factors in Raw264.7 cells.

[0116] The RNA of Raw264.7 cells was extracted using a total RNA extraction kit (GenElute™, Sigma). The specific method was referred to the kit manual. The extracted RNA was reverse transcribed into cDNA using a reverse transcription kit, and then the cDNA was used as a template for real-time fluorescence quantitative PCR to analyze the transcription levels of TNF-α, IL-1β, IL-6, and IL-10. The designed synthetic primers are shown in Table 3 (synthesized by Beijing Qingke Xinye Biotechnology Co., Ltd.). The real-time fluorescence quantitative PCR reaction system and conditions were referred to the kit manual, with (3-actin universal primer amplification as the internal reference and 2 -∆∆Ct Methods The relative expression of each gene was calculated.

[0117] Table 3

[0118] Primer name Sequence (5'→3') TNF-α-F cccctccctctcatcacttc, as shown in SEQ ID NO.2 TNF-α-R cctcctttcctaccacctc, as shown in SEQ ID NO.3 IL-1β-F tcccaccttttcacactcatc, as shown in SEQ ID NO.4 IL-1β-R tcatctcctcctcccacatt, as shown in SEQ ID NO.5 IL-6-F ggaccccaccaacaaccata, as shown in SEQ ID NO.6 IL-6-R ttctcaccaccatcactcc, as shown in SEQ ID NO.7 IL-10-F cacacaaccatcccccacaa, as shown in SEQ ID NO.8 IL-10-R cctccactcccttcctctta, as shown in SEQ ID NO.9 β-actin-F ccaccatctacccacccatt, as shown in SEQ ID NO.10 β-actin-R cccactcatcctactcctcc, as shown in SEQ ID NO.11

[0119] 6. Results

[0120] The vesicle suspensions and freeze-dried products prepared in Examples 1-4 of the present application and Comparative Examples 1-2 were tested using the above method, and the results are as follows.

[0121] Table 4

[0122] Implementation Plasmin activity (U / g) Oryzanol(mg / g) Polysaccharide (mg / g) Water-soluble cellulose (mg / g) Niacin (mg / g) Example 1 3621±125a 4.62±0.35b 72.35±1.68b 267.3±41.7b 1.32±0.061b Example 2 3762±83a 4.49±0.27b 91.47±1.26a 296.7±68.2ab 1.63±0.087a Example 3 3935±59a 4.76±0.35a 87.04±2.72ab 325.4±55.3a 1.71±0.054a Example 4 3711±74a 4.88±0.19a 84.61±3.85ab 312.8±61.3a 1.54±0.046b Comparative Example 1 2308±69b 1.03±0.16c 18.70±2.92c 130.7±27.4c 0.42±0.024c Comparative Example 2 2138±108b 0.79±0.22c 9.65±1.94d 123.8±39.4c 0.38±0.014c

[0123] Table 4 lists the content of fibrinolytic enzyme activity, oryzanol, polysaccharide, water-soluble cellulose and nicotinic acid in the freeze-dried products. The contents of Examples 1-4 are significantly higher than those of Comparative Example 1 or Comparative Example 2. Specifically, Comparative Example 1 and Comparative Example 2 both use commercial Bacillus subtilis Bacillus subtilis CMCC(B)63501, and comparative example 1 uses a common liquid culture medium. Since comparative examples 1 and 2 use commercial strains and common liquid culture medium, the content of relevant active ingredients in the freeze-dried products obtained is relatively low. This shows that the Bacillus subtilis provided in the examples of the present application Bacillus subtilis -1 CGMCC No.20831 can be fermented to produce freeze-dried products with high content of active ingredients.

[0124] Plasmin is a hydrolytic enzyme that can degrade fibrin gel. It plays an important role in preventing blood circulation from coagulation. If a normal human body has thrombosis due to various reasons, plasmin will appear in the blood to dissolve excess thrombus. Its function is to hydrolyze multiple coagulation factors. The process of hydrolyzing coagulation factors includes the production of plasminogen and the degradation of thrombus. Oryzanol can prevent the synthesis of cholesterol in the body, protect the skin, promote the circulation function of skin microvessels, and has antioxidant, antiseptic, and mildew-proof effects. It has a good therapeutic effect on sequelae of concussion, premenstrual tension and hyperlipidemia. Polysaccharides can significantly reduce the level of triglycerides and cholesterol in the human body. Soluble cellulose can absorb bile salts and cholesterol; niacin has the effect of dilating small blood vessels in the body to reduce triglycerides and cholesterol, and can also significantly reduce LDL and increase GDL content. In addition to its antioxidant effect in the body, it also reduces serum cholesterol.

[0125] Table 5

[0126]

[0127] As shown in Table 5, after 10 μg / mL of the vesicles provided in Examples 1-4 (Comparative Examples 1-2 did not produce obvious vesicles) were co-cultured with DC2.4 cells and Raw 264.7 cells for 24 hours, they had obvious proliferation effects on DC 2.4 cells and Raw 264.7 cells. The commercial Bacillus subtilis provided in Comparative Examples 1 or 2 did not have obvious effects on promoting the proliferation of DC 2.4 cells and Raw264.7 cells.

[0128] Table 5 also lists the results of the transcription level of inflammatory factors in Raw264.7 cells after the vesicles or cells provided in each embodiment and comparative example were co-cultured with Raw264.7 cells. Compared with the negative control group, the 5 μg / mL vesicles provided in Examples 1-4 significantly promoted the expression of inflammatory factors in Raw264.7 cells, while the promoting effect of Comparative Example 1-2 was not obvious, especially for IL-6 and IL-10 ("-" in Table 5 means not detected).

[0129] The main function of macrophages is to phagocytose (i.e., engulf and digest) cell debris and pathogens in the form of fixed or free cells, and activate lymphocytes or other immune cells to respond to pathogens, playing a very important role in innate immunity. The Bacillus subtilis strain disclosed in the examples of this application can promote the proliferation of two types of macrophages, DC2.4 cells and Raw 264.7 cells, and the secretion of inflammatory factors. This may be related to the ability of vesicles to dissolve the phagosome membrane of macrophages and promote the escape of bacteria from macrophages to grow and reproduce in the cytoplasm. This immune characteristic is mainly related to macrophages, which stimulates the immune response of these macrophages and has an immune-promoting effect.

[0130] In vivo test

[0131] 1. Introduction to experimental animals

[0132] Healthy SD rats, with an initial body weight of about 100 g, were purchased from Guangdong Experimental Animal Research Institute and kept in an SPF animal laboratory at 21±2°C, relative humidity: 30-70%, photoperiod: 12 h light / 12 h dark, ventilation condition: 10-11 times / h. After feeding for 1 axis, the rats' activities and mental state were observed, and their body weight was recorded.

[0133] 2. Test products

[0134] The above Bacillus subtilis -1CGMCC No.20831 After fermentation, the fermentation liquid was centrifuged, the precipitate was collected, a freeze-drying protective agent was added, and freeze-dried to obtain Bacillus subtilis -1CGMCC No.20831 bacterial powder, and then added with 20wt% of wheat bran powder and 1.5wt% of wheat germ oil to serve as the test sample of Example 5.

[0135] Bacillus subtilis (Collection No. CMCC(B)63501 bacterial powder, 20 wt% of wheat bran powder and 1.5 wt% of wheat germ oil were added to the bacterial powder as the test sample of Comparative Example 3.

[0136] In addition, wheat bran powder and wheat germ oil were used as test samples in Comparative Examples 4 and 5, respectively.

[0137] 3. Establishment of obesity model SD rats

[0138] After the 1-week adaptation period, the SD rats were transferred to the PC rat cages in the air-purified cage IVC and entered the modeling period. The rats were randomly divided into a normal group, a model group, and an experimental group. The rats in the model group and the experimental group were given a high-calorie diet, and the rats in the normal group were given a normal diet.

[0139] After two weeks of feeding, the rats with the highest and lowest weights were eliminated from the normal group. The rats with the highest and lowest weights were also eliminated from the model group and the experimental group. Feeding was continued for 6 to 8 weeks until the average weight of the rats in the model group and the experimental group was more than 1.2 times the average weight of the rats in the normal group, indicating that the obesity model SD rats was successfully established.

[0140] Normal feed contains: ≧18% crude protein, ≧4% crude fat, ≦5% crude fiber, ≦5% crude ash, 1.0~1.8% calcium content, 0.6~1.2% phosphorus content and 55% nitrogen-free extract, with a total energy of 3276 Kcal / k.

[0141] The high-calorie feed contains: ≧18% crude protein, ≧17.56% crude fat, ≦5% crude fiber, 15% sucrose, ≦8% crude ash, 1.0~1.8% calcium content, 0.6~1.2% phosphorus content and 26% nitrogen-free extract, with a total energy of 4048 Kcal / kg.

[0142] 4. Drug administration to obese rats

[0143] The rats in the model group continued to be fed with high-calorie diet, and the rats in the normal group continued to be fed with normal diet.

[0144] The rats in the experimental group continued to be fed with high-calorie diets, and their body weights were weighed regularly every day. The gavage volume was calculated, and the rats were given the corresponding test substances for 6 weeks. During the gavage period, the rats were free to eat and drink. The gavage dose was 2.5 g / (kg·body weight·day). The rats' food intake and leftover food were recorded every week, their body weights were weighed once, fresh feces were collected once, and the bedding was changed twice.

[0145] Before the end of the experiment, all rats were fasted but not watered for 12 hours. After weighing, 1% sodium pentobarbital solution was injected subcutaneously in the abdomen for anesthesia. Then, 10 mL of blood was collected from the abdominal aorta by laparotomy. Liver slices were quickly made, and the large and small intestines were separated. The small intestine was placed in a marked sterile sample collection bag and stored in a -20℃ liquid nitrogen environment. The perinephric fat and perinephric fat of the rats were quickly separated, and the body fat rate was detected. At the same time, the main liver tissue of the rats was removed, slices were made, and oil red staining was performed.

[0146] After 6 weeks of dietary intervention, the rats with nutritional obesity were fasted for 12 hours but not water, and then anesthetized and dissected. The blood was collected from the abdominal aorta with a blood collection needle and collected into a blood collection tube. The collected blood was centrifuged at 3000 r / min at 4°C for 15 minutes in a refrigerated centrifuge, and the supernatant was divided into 2 mL centrifuge tubes, sealed with sealing film and stored in a -20°C refrigerator. The serum fasting blood glucose GLU, serum total cholesterol TC, high-density lipoprotein cholesterol HDL-C, low-density lipoprotein cholesterol LDL-C, triglycerides TG and alanine aminotransferase (ALT) were measured using an automatic biochemical analyzer.

[0147] 5. Determination of the number of peripheral blood lymphocytes

[0148] Every week after the start of the drug administration experiment, 6 rats in each group were randomly drawn for blood sampling by venous needle puncture and blood-making membrane was pushed, which was quickly blown dry and fixed with anhydrous methanol for 1 min. Then, the blood was stained with Giemsa staining solution diluted 10 times with 0.05 mol / L PBS at pH 6.8 for 30 min, washed with water, dried and routinely classified and counted. According to the lymphocyte white fraction (%), the absolute number of lymphocytes (lymphocyte number × 10 -3 / mm 3 ).

[0149] 6. Serum IgG and intestinal mucosal secretory immunoglobulin A (sIgA) determination

[0150] Rats in each group were randomly selected, blood was collected from the heart, and the blood was centrifuged at 3000 r / min for 5 min. The supernatant was stored at -20°C as a serum test sample, and the content therein was determined using an IgG kit (Cat. No.: ER1079, Finn Biotechnology).

[0151] For the slaughtered rats, the small intestine contents were rinsed with sterile distilled water, and 0.5 g of intestinal membrane tissue was aseptically scraped from each rat, diluted 1-fold with sterile phosphate buffer at pH 7.4, and centrifuged at 8000 r / min for 10 min. The supernatant was collected and preserved, and the sIgA content was measured using an sIgA kit (eBioscience).

[0152] 7. Results

[0153] Table 6

[0154]

[0155] As shown in Table 6, after 6 weeks of administration to obese rats, the body weight of the model group increased significantly compared with the normal group, and the body fat rate and liver fat droplet area increased significantly, indicating that the model was successfully established. In the experimental group, the test product provided in Example 5 was able to counteract the rats' intake of high-calorie feed energy, and no obvious symptoms of increased body fat rate, liver fat droplet area and body weight were observed, which were significantly lower than those in the model group, indicating that the test product provided in Example 5 of the present application was effective. Bacillus subtilis -1CGMCCNo.20831 bacterial powder counteracts the tendency of obesity in rats and has a weight loss effect.

[0156] Table 7 Blood glucose and blood lipid levels of rats after the experiment

[0157]

[0158] Table 8 Blood glucose and blood lipid levels of rats after the experiment

[0159]

[0160] As shown in Tables 7 and 8, compared with the normal group, the levels of GLU, TG, TC, LDL, HDL and ALT in the model group rats were significantly increased, indicating that the obese SD model rats were successfully established. Bacillus subtilis After intervention with -1CGMCC No.20831 powder, the blood sugar and blood lipid levels of obese rats were significantly reduced, and their obesity symptoms were improved.

[0161] Table 9 As shown in Table 9, compared with the normal group, the peripheral blood lymphocytes, serum immunoglobulins and intestinal mucosal secretory immunoglobulin A levels of the model group rats were significantly decreased, indicating that the immunity of obese rats was reduced. Bacillus subtilis -1CGMCCNo.20831 bacterial powder intervention, the peripheral blood lymphocytes, serum immunoglobulins and intestinal mucosal secretory immunoglobulin A increased to varying degrees, indicating that the Bacillus subtilis provided in this application has the effect of improving the decreased immunity of obese rats.

[0162] In summary, the present invention screened a strain of Bacillus subtilis from the sludge in shrimp breeding ponds. Bacillus subtilis -1CGMCC No.20831, not only has the physiological and biochemical activities of conventional Bacillus subtilis, but also can produce extracellular vesicles that promote macrophage proliferation and the expression of inflammatory factors, and ferments wheat bran powder and wheat germ oil to obtain freeze-dried products with high content of fibrinolytic enzyme activity, oryzanol, polysaccharides, water-soluble cellulose and niacin.

[0163] In addition, the present invention also confirms the Bacillus subtilis obtained by screening in the present invention through animal experiments. Bacillus subtilis -1CGMCC No.20831 can alleviate the abnormal blood sugar, blood lipid content, and liver function of obese rats, and improve the physiological activity of decreased immunity in obese rats, and has the application prospect of being used in animal feed, health products and medicines.

[0164] The above is only a preferred specific implementation of the present application, but the protection scope of the present application is not limited thereto. Any changes or substitutions that can be easily conceived by any technician familiar with the technical field within the technical scope disclosed in the present application should be covered within the protection scope of the present application.

Claims

1. A fermentation method for a fermented product, which is obtained by fermentation with Bacillus subtilis CGMCC No. 20831, the fermentation method comprising the following steps: preparing a seed culture solution and a fermentation culture solution, wherein the seed culture solution contains wheat germ oil, and the fermentation culture solution contains wheat bran powder and wheat germ oil; preparing a seed suspension, wherein the seed suspension is obtained by activating the preserved Bacillus subtilis CGMCC No.20831 and then inoculating it into the seed culture solution for culturing; Obtaining a fermentation broth, wherein the fermentation broth is obtained by transferring the seed suspension to the fermentation broth for fermentation; Obtaining a dry product and vesicles, wherein the dry product and vesicles are obtained by purifying the fermentation broth; The steps of obtaining the dried product and vesicles specifically include: The fermentation broth was centrifuged at 4°C and 15,000×g for 20 min, and the supernatant was collected. The supernatant was ultrafiltered using a 100 KD filter membrane to obtain a filtrate and a concentrate containing extracellular vesicles; The concentrated solution is purified to obtain extracellular vesicles; The filtrate is subjected to suspended evaporation under reduced pressure and freeze-dried to obtain a freeze-dried product.

2. The fermentation method according to claim 1, characterized in that The seed culture solution contains 1.5wt% glucose, 1.0wt% peptone, 0.1wt% KH2PO4, 0.1wt% K2HPO4, 0.05wt% MgSO4, 0.02wt% CaC12 and 0.01v / v% wheat germ oil.

3. The fermentation method according to claim 2, characterized in that The fermentation broth comprises 1.5wt% starch, 1.5wt% wheat bran powder, 1.0wt% peptone, 0.1wt% KH2PO4, 0.1wt% K2HPO4, 0.05wt% MgSO4, 0.02wt% CaC12 and 0.01v / v% wheat germ oil.

4. The fermentation method according to claim 3, characterized in that The step of purifying the concentrated solution to obtain extracellular vesicles comprises: The concentrate was centrifuged at 4°C, 100,000 × g for 10 min, and the supernatant was collected; The supernatant was placed in a density gradient centrifugation medium with a concentration gradient of 10% to 55% for density gradient ultracentrifugation at 4°C and 200,000 × g for 12 h; By measuring the nanoparticles in each layer of the layered material obtained by centrifugation and collecting the gradient interval with more nanoparticles, the enriched vesicle particles can be obtained; The solution in the vesicle aggregation area is centrifuged at 4°C and 180,000×g for 2 h to enrich the precipitate to obtain the extracellular vesicles.

Citation Information

Patent Citations

  • Bacillus subtilis, method for preparing bacillus subtilis and its using method

    CN1782068A

  • A Novel Bacillus subtilis TSD and methods for preparing Doenjang using the same

    KR102240109B1